Is ERNA or ALVR more profitable?

AlloVir's return on equity of -71.03% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -305.93% -169.86% AlloVir N/A -71.03% -61.27%

Is SKYE or ERNA more profitable?

Skye Bioscience's return on equity of -244.83% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -244.83% -170.10% Ernexa Therapeutics N/A -305.93% -169.86%

Do analysts prefer ERNA or PLUR?

Ernexa Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 638.92%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Ernexa Therapeutics is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ERNA or PLUR more profitable?

Ernexa Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -305.93% -169.86% Pluri -2,162.08% N/A -106.59%

Do analysts prefer TPST or ERNA?

Ernexa Therapeutics has a consensus price target of $30.00, indicating a potential upside of 638.92%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ernexa Therapeutics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TPST or ERNA more profitable?

Ernexa Therapeutics' return on equity of -305.93% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -576.56% -134.99% Ernexa Therapeutics N/A -305.93% -169.86%

Ernexa Therapeutics (ERNA) Competitors

$4.06 -0.21 (-4.92%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$4.42 +0.36 (+8.97%)

As of 08:30 AM Eastern

Compare

ERNA vs. CELU, ALVR, SKYE, PLUR, and TPST

Should you buy Ernexa Therapeutics stock or one of its competitors? Ernexa Therapeutics's main competitors and comparable companies include Celularity (CELU), AlloVir (ALVR), Skye Bioscience (SKYE), Pluri (PLUR), and Tempest Therapeutics (TPST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ernexa Therapeutics compare to Celularity?

Ernexa Therapeutics (NASDAQ:ERNA) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Ernexa Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 638.92%. Celularity has a consensus target price of $6.00, indicating a potential upside of 762.07%. Given Celularity's higher probable upside, analysts plainly believe Celularity is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ernexa Therapeutics has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
Celularity	-345.45%	N/A	-77.94%

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by company insiders. Comparatively, 17.3% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ernexa Therapeutics has higher earnings, but lower revenue than Celularity. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	11.41	-$14.08M	-$14.35	N/A
Celularity	$26.55M	0.76	-$91.72M	-$3.33	N/A

In the previous week, Ernexa Therapeutics and Ernexa Therapeutics both had 1 articles in the media. Celularity's average media sentiment score of 1.89 beat Ernexa Therapeutics' score of 1.87 indicating that Celularity is being referred to more favorably in the news media.

Company	Overall Sentiment
Ernexa Therapeutics	Very Positive
Celularity	Very Positive

Ernexa Therapeutics has a beta of 2.57, meaning that its share price is 157% more volatile than the broader market. Comparatively, Celularity has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

Summary

Celularity beats Ernexa Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Ernexa Therapeutics compare to AlloVir?

Ernexa Therapeutics (NASDAQ:ERNA) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

AlloVir's return on equity of -71.03% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
AlloVir	N/A	-71.03%	-61.27%

Ernexa Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 638.92%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Ernexa Therapeutics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Ernexa Therapeutics had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Ernexa Therapeutics and 0 mentions for AlloVir. Ernexa Therapeutics' average media sentiment score of 1.87 beat AlloVir's score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Ernexa Therapeutics	Very Positive
AlloVir	Neutral

Ernexa Therapeutics has higher revenue and earnings than AlloVir. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	11.41	-$14.08M	-$14.35	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Ernexa Therapeutics has a beta of 2.57, indicating that its stock price is 157% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

Summary

Ernexa Therapeutics beats AlloVir on 10 of the 14 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Skye Bioscience has a beta of 2.97, indicating that its stock price is 197% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.57, indicating that its stock price is 157% more volatile than the broader market.

In the previous week, Skye Bioscience had 5 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 6 mentions for Skye Bioscience and 1 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 1.87 beat Skye Bioscience's score of 0.95 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Skye Bioscience	Positive
Ernexa Therapeutics	Very Positive

Skye Bioscience currently has a consensus price target of $8.00, suggesting a potential upside of 1,827.25%. Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 638.92%. Given Skye Bioscience's stronger consensus rating and higher probable upside, equities analysts plainly believe Skye Bioscience is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Skye Bioscience's return on equity of -244.83% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-244.83%	-170.10%
Ernexa Therapeutics	N/A	-305.93%	-169.86%

Ernexa Therapeutics has higher revenue and earnings than Skye Bioscience. Skye Bioscience is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.27	N/A
Ernexa Therapeutics	$580K	11.41	-$14.08M	-$14.35	N/A

Summary

Skye Bioscience beats Ernexa Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Pluri?

Ernexa Therapeutics (NASDAQ:ERNA) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Ernexa Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
Pluri	-2,162.08%	N/A	-106.59%

Ernexa Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 638.92%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Ernexa Therapeutics is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by company insiders. Comparatively, 43.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ernexa Therapeutics has a beta of 2.57, indicating that its share price is 157% more volatile than the broader market. Comparatively, Pluri has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

In the previous week, Pluri had 2 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 3 mentions for Pluri and 1 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 1.87 beat Pluri's score of 1.05 indicating that Ernexa Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Ernexa Therapeutics	Very Positive
Pluri	Positive

Ernexa Therapeutics has higher earnings, but lower revenue than Pluri. Pluri is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	11.41	-$14.08M	-$14.35	N/A
Pluri	$1.34M	12.88	-$22.58M	-$4.53	N/A

Summary

Ernexa Therapeutics beats Pluri on 9 of the 16 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Tempest Therapeutics has a beta of -1.72, meaning that its stock price is 272% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.57, meaning that its stock price is 157% more volatile than the broader market.

Ernexa Therapeutics has a consensus price target of $30.00, indicating a potential upside of 638.92%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ernexa Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ernexa Therapeutics has higher revenue and earnings than Tempest Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A
Ernexa Therapeutics	$580K	11.41	-$14.08M	-$14.35	N/A

Ernexa Therapeutics' return on equity of -305.93% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-576.56%	-134.99%
Ernexa Therapeutics	N/A	-305.93%	-169.86%

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 36.2% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Tempest Therapeutics had 3 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 4 mentions for Tempest Therapeutics and 1 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 1.87 beat Tempest Therapeutics' score of 0.22 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tempest Therapeutics	Neutral
Ernexa Therapeutics	Very Positive

Summary

Ernexa Therapeutics beats Tempest Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Ernexa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERNA vs. The Competition

Export

Metric	Ernexa Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.97M	$3.73B	$7.03B	$13.03B
Dividend Yield	N/A	3.69%	2.56%	10.62%
P/E Ratio	-0.28	11.49	270.85	25.41
Price / Sales	11.41	1,171.59	559.55	69.76
Price / Cash	N/A	45.11	28.87	38.47
Price / Book	0.53	17.19	11.07	6.51
Net Income	-$14.08M	-$13.19M	$3.45B	$347.22M
7 Day Performance	-7.52%	0.93%	0.60%	1.27%
1 Month Performance	-36.76%	2.64%	2.07%	2.72%
1 Year Performance	-89.91%	53.99%	61.59%	21.85%

Ernexa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ERNA Ernexa Therapeutics	3.1132 of 5 stars	$4.06 -4.9%	$30.00 +638.9%	-89.8%	$6.97M	$580K	N/A	10	Positive News
CELU Celularity	2.568 of 5 stars	$0.69 -1.5%	$6.00 +769.6%	-80.0%	$20.27M	$26.55M	N/A	220	Positive News Gap Down
ALVR AlloVir	N/A	$3.97 +0.8%	N/A	+65.9%	$20.02M	N/A	N/A	110	Gap Up
SKYE Skye Bioscience	1.9172 of 5 stars	$0.55 +1.5%	$8.50 +1,448.6%	-88.2%	$19.01M	N/A	N/A	11	Earnings Report Gap Up
PLUR Pluri	1.0787 of 5 stars	$1.63 -7.1%	N/A	-67.8%	$18.88M	$1.34M	N/A	150	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ERNA) was last updated on 8/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. CELU, ALVR, SKYE, PLUR, and TPST

How does Ernexa Therapeutics compare to Celularity?

Summary

How does Ernexa Therapeutics compare to AlloVir?

Summary

How does Ernexa Therapeutics compare to Skye Bioscience?

Summary

How does Ernexa Therapeutics compare to Pluri?

Summary

How does Ernexa Therapeutics compare to Tempest Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. CELU, ALVR, SKYE, PLUR, and TPST

How does Ernexa Therapeutics compare to Celularity?

Do analysts recommend ERNA or CELU?

Is ERNA or CELU more profitable?

Do insiders and institutionals have more ownership in ERNA or CELU?

Which has better earnings & valuation, ERNA or CELU?

Does the media favor ERNA or CELU?

Which has more volatility and risk, ERNA or CELU?

Summary

How does Ernexa Therapeutics compare to AlloVir?

Is ERNA or ALVR more profitable?

Do analysts rate ERNA or ALVR?

Do institutionals & insiders hold more shares of ERNA or ALVR?

Does the media prefer ERNA or ALVR?

Which has better earnings & valuation, ERNA or ALVR?

Which has more risk and volatility, ERNA or ALVR?

Summary

How does Ernexa Therapeutics compare to Skye Bioscience?

Which has more risk & volatility, SKYE or ERNA?

Does the media favor SKYE or ERNA?

Do analysts rate SKYE or ERNA?

Do insiders and institutionals hold more shares of SKYE or ERNA?

Is SKYE or ERNA more profitable?

Which has higher valuation & earnings, SKYE or ERNA?

Summary

How does Ernexa Therapeutics compare to Pluri?

Is ERNA or PLUR more profitable?

Do analysts prefer ERNA or PLUR?

Do insiders & institutionals have more ownership in ERNA or PLUR?

Which has more risk & volatility, ERNA or PLUR?

Does the media refer more to ERNA or PLUR?

Which has stronger valuation and earnings, ERNA or PLUR?

Summary

How does Ernexa Therapeutics compare to Tempest Therapeutics?

Which has more volatility & risk, TPST or ERNA?

Do analysts prefer TPST or ERNA?

Which has stronger valuation and earnings, TPST or ERNA?

Is TPST or ERNA more profitable?

Do insiders and institutionals believe in TPST or ERNA?

Does the media favor TPST or ERNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools